Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.
Novo Nordisk on Tuesday received a broker downgrade, with the analysts arguing that its status as a duopoly in both diabetes and weight loss are under threat.
📰 Original Source
Read full article at Marketwatch →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.